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Background: We aimed to evaluate early clinical and pathological results for treating locally advanced rectal cancer with
bevacizumab and neoadjuvant concurrent chemoradiotherapy using the technique of prone-position volumetric
modulated arc therapy and to compare the toxicity of volumetric modulated arc therapy with that of supine-position
four-field box radiotherapy.
Methods: Twelve patients with stage IIA to IVA rectal adenocarcinoma, treated with neoadjuvant concurrent
chemoradiotherapy (45 Gy in 25 fractions to the rectal tumor and pelvic lymphatics) and bevacizumab, were
prospectively enrolled. Chemotherapy included FOLFOX (leucovorin, fluorouracil, and oxaliplatin) (n =11) and
5-fluorouracil (n =1). All patients received prone-position volumetric modulated arc therapy. A historical cohort
treated with supine-position box radiotherapy, including six other patients treated with bevacizumab-based
concurrent chemoradiotherapy in our hospital, was used for comparison. Setup errors, toxicities, and potential
biomarkers were evaluated.
Results: All patients completed neoadjuvant concurrent chemoradiotherapy and underwent total mesorectal excision.
Four (33.3%) patients had pathological complete response. Significantly more grade 2 or 3 diarrhea was associated with
the supine-box technique (5/6 versus 2/12, P =0.01). The magnitude of setup errors was similar between the supine-box
and prone volumetric modulated arc therapy techniques. The estimated 2-year survival and 2-year failure-free survival
rates were 100% and 72.9% in the prone volumetric modulated arc therapy group and 66.7% and 66.7% in the supine
box group, respectively.
Conclusions: The early clinical outcome has been encouraging. Volumetric modulated arc therapy in prone-positioned
patients was technically advantageous and reduced bowel toxicity.
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Neoadjuvant concurrent chemoradiotherapy has become
the standard for locally advanced rectal cancer care. Previ-
ous studies showed that preoperative concurrent chemora-
diotherapy reduced the recurrence rate and increased the
sphincter preservation rate, when compared with postopera-
tive concurrent chemoradiotherapy [1,2]. The use of various* Correspondence: jasoncheng@ntu.edu.tw
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vestigated in conjunction with neoadjuvant concurrent che-
moradiotherapy. Nevertheless, treatment-related toxicities
have limited the success of these combination therapies.
Bevacizumab, an anti-vascular endothelial growth fac-
tor monoclonal antibody, is widely used in metastatic
colorectal cancer [3,4]. Although it augments the thera-
peutic effect of ionizing radiation [5,6], bevacizumab has
been shown to have significant gastrointestinal toxicities
when combined with radiotherapy [7]. In several studies
evaluating the efficacy and safety of concurrent chemo-
radiotherapy combined with bevacizumab for rectaltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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was reported for capecitabine or fluorouracil with beva-
cizumab in neoadjuvant concurrent chemoradiotherapy
[8,9], while some excessive toxicities were still reported
for capecitabine and bevacizumab or bevacizumab, oxali-
platin and 5-fluorouracil in neoadjuvant concurrent che-
moradiotherapy [10,11].
Intensity-modulated radiation therapy has gradually re-
placed traditional four-field box radiotherapy in rectal
cancer treatment because it improves dose distribution
and reduces bowel exposure [12,13]. Volumetric modu-
lated arc therapy, a recently developed technique involving
arc intensity-modulated radiation therapy delivery, has
been shown to further improve dose conformity and
organ sparing [14,15]. Prone positioning on a belly board
has effectively reduced bowel doses in radiotherapy for
pelvic malignancies [13,16-18]. The clinical outcome of
prone-position volumetric modulated arc therapy has not
been assessed for rectal cancer. The aims of this study
were, firstly, to evaluate early pathological and clinical out-
come in patients with locally advanced rectal cancer
treated with combined neoadjuvant bevacizumab and
concurrent chemoradiotherapy using prone-position volu-
metric modulated arc therapy and, secondly, to compare
the treatment-related toxicity of the supine-position box




Eligible patients had histologically confirmed rectal adeno-
carcinoma within 15 cm above the anal verge. Pretreatment
staging workup included complete physical examination;
chest X-ray; colonoscopy; computed tomography or mag-
netic resonance imaging of the abdomen and pelvis; and
optional positron emission tomography. Endorectal ultra-
sound was obtained for tumor (T) and node (N) stages in
patients by computed tomography of the pelvis. Patients
with T3 or T4 or N1 or N2 disease were included. An East-
ern Cooperative Oncology Group performance status of 0
or 1 was required. All patients gave their informed consent.
Radiotherapy technique
Treatment was delivered with a 10 MV photon beam. We
used an Elekta Synergy® linear accelerator upgraded with a
volumetric modulated arc therapy function (Elekta Oncol-
ogy System Ltd., Crawley, West Sussex, UK) for all patients
receiving volumetric modulated arc therapy. For the six pa-
tients receiving three-dimensional therapy, we used the
Elekta Synergy® linear accelerator for five patients and a Sie-
mens PRIMUS linear accelerator (Siemens Medical System
Inc., Concord, CA, USA) for one patient. The total dose
was 45 Gy, given in 25 fractions of 1.8 Gy (one fraction per
day; five fractions per week). Before March 2010, the four-field box technique was used in the supine position. After
March 2010, the volumetric modulated arc therapy tech-
nique was used in the prone position on a belly board. Our
institutional review board approved the protocol of this
study. The volumetric modulated arc therapy plans were
optimized using Pinnacle3 version 9.0 planning system
software (ADAC Laboratories, Philips Medical Systems,
Milpitas, CA, USA). We used a collapse cone convolution
algorithm and a grid size of 4 mm [19]. Cone-beam com-
puted tomography or orthogonal views were required for
image guidance in all patients.
Simulation and target definition
Patients were instructed to maintain a tolerably full bladder.
A belly board was used to move the small bowels away
from the radiation field for patients receiving volumetric
modulated arc therapy. A planning computed tomogram
(maximum slice thickness, 5 mm) was acquired using the
same immobilization technique as for treatment.
The gross tumor volume was defined as all known
gross disease, as determined from a combination of im-
aging studies. The clinical target volume was defined as
the gross tumor volume plus areas considered at signifi-
cant risk of microscopic disease. The clinical target vol-
ume for a T3 tumor included all gross disease (rectal
and nodal) as well as the internal iliac lymph nodes and
the mesorectum (perirectal fat and presacral space). The
clinical target volume for a T4 tumor included the same
structures as defined in the clinical target volume for a
T3 tumor and also the external iliac lymph nodes. To be
more specific, the rectal clinical target volume was de-
fined as the rectal gross tumor volume plus a 1.5 cm
margin radially and a 2.5 cm margin craniocaudally. The
nodal clinical target volume was defined as the nodal
gross tumor volume plus a 1.5-cm symmetrical expan-
sion of this volume. The clinical target volumes around
vessels were defined as vessel volumes plus a 0.7-cm ex-
pansion of these volumes. The presacral lymphatic clin-
ical target volume was contoured from mid S1 to S5.
The planning target volume was the clinical target vol-
ume with a 5-mm margin.
The organs at risk, including the small bowel, bladder,
prostate, uterus, and bilateral femurs were contoured ac-
cordingly. When the clinical target volume overlapped the
small bowel, the clinical target volume was manually
trimmed to reduce the exposure of the small bowel. The
planning target volume was not modified when it over-
lapped the organs at risk.
Treatment parameters
For four-field box radiotherapy, the prescribed dose was de-
livered to the field isocenter. The dose weightings (ratios)
for the anterior-posterior opposed beams and bilaterally op-
posed beams were either 1:1 or 6:4. For volumetric
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and two patients had three partial arcs. We used the volu-
metric modulated arc therapy technique with partial arcs
by excluding gantry angles between 120° and 240° to treat
patients in the prone position on a belly board, mainly to
reduce the radiation dose to the urinary bladder and small
bowels. This planning method helps achieve conformity of
targets and simultaneously spares the critical organs.
Chemotherapy
All patients received bevacizumab (5 mg/kg given every 2
to 3 weeks, for a median of five cycles) and oxaliplatin, 5-
fluorouracil, and leucovorin (FOLFOX: 5-fluorouracil 1600
to 2800 mg/m2, oxaliplatin 40 to 85 mg/m2, and leucovorin
300 mg/m2; every 2 to 3 weeks for a median of five cycles),
except that one patient was only given 5-fluorouracil, owing
to old age.
Surgery
Total mesorectal excision was performed 6 to 8 weeks
after the completion of concurrent chemoradiotherapy.
Rectum and pelvic lymphatics were removed. The surgi-
cal technique was either abdominoperineal resection or
low anterior resection. Total mesorectal excisions were
conducted laparoscopically in 13 patients.
Measurement of setup errors
Image-guided tools were used to measure the absolute
values of displacements in the superior-inferior, left-right,
and anterior-posterior directions. For patients receiving
volumetric modulated arc therapy, we used cone-beam
computed tomography with an Elekta Synergy® X-ray vol-
ume imaging system (Elekta Oncology System Ltd., Crawley,
West Sussex, UK) in all patients to evaluate setup errors.
Approximately 650 projections were collected during a 360°
rotation of the gantry in a clockwise direction. All cone-
beam computed tomograms were compared with simula-
tion computed tomograms using the pelvic bony structure
as a reference. Electronic portal images were used in those
receiving three-dimensional conformal radiotherapy. We
compared the electronic portal images with digitally recon-
structed radiographs from computed tomograms, by using
the pelvic bony landmarks including the sacral edge and the
pelvic ring, to measure and correct setup errors. With the
average displacements from each patient, a group average
was calculated for each of these three directions.
Toxicity and outcome assessments
Toxicity was evaluated weekly during concurrent chemora-
diotherapy and was graded using Common Terminology
Criteria for Adverse Events, version 4.0. The primary end-
points were toxicity and pathological response, including
pathological complete response and downstaging rates. Sec-
ondary endpoints included failure-free survival and overallsurvival. Survival was calculated from the first day of radio-
therapy to the dates of the last follow-up visit or any recur-
rence (for failure-free survival) and death (for overall
survival).
Immunohistochemical staining
The pre-concurrent chemoradiotherapy biopsy sample
and post-concurrent chemoradiotherapy surgical tissues
were stained immunohistochemically using monoclonal
antibodies against CD34 (Dako Denmark A/S, Glostrup,
Denmark), Akt (Cell Signaling Technology Inc., Danvers,
MA, USA), epidermal growth factor receptor (Dako
Denmark A/S, Glostrup, Denmark), and vascular endo-
thelial growth factor receptor 2 (Cell Signaling Technol-
ogy Inc., Danvers, MA, USA). The slices were reviewed
by an experienced pathologist at our institution.
Statistical analysis
The statistical analysis was conducted using IBM SPSS sta-
tistics v.20.0 (IBM Corp., Armonk, NY, USA). Fisher’s exact
test was used for the analysis of contingency tables. Student’s
t test was used to evaluate differences in the volume receiv-
ing a certain dose or magnitude of setup errors between the
supine- and prone-position groups. Kaplan-Meier analysis
was used for survival comparisons. Differences were consid-
ered significant at P <0.05.
Results
Patient characteristics
Twelve patients with stage IIA to IVA rectal adenocar-
cinoma treated with neoadjuvant concurrent chemora-
diotherapy and bevacizumab from March 2010 to March
2012 were prospectively enrolled in this study and were
treated in the prone position with volumetric modulated
arc therapy (prone volumetric modulated arc therapy).
We also retrospectively collected details of all patients
treated with neoadjuvant concurrent chemoradiotherapy
and bevacizumab before the new technique was used
and identified six patients, who all received four-field
box radiotherapy in the supine position (supine box).
The median follow-up time was 22.4 and 34.2 months in
the prone volumetric modulated arc therapy and supine
box cohorts, respectively. Patient characteristics (Table 1)
included clinical T3 or T4 disease (n =17), clinical nodal
involvement (n =14), and tumor location within 5 cm
above the anal verge (n =6). The average delivery time of
volumetric modulated arc therapy was 285 ± 46 s. The
group averages of displacements in the superior-inferior,
left-right, anterior-posterior directions (0.27 ± 0.09 cm,
0.20 ± 0.10 cm, and 0.34 ± 0.15 cm in the prone-position
volumetric modulated arc therapy group, and 0.16 ±
0.18 cm, 0.14 ± 0.09 cm, and 0.24 ± 0.17 cm in
the supine-position box group, respectively) were not
Table 1 Patient characteristics in different cohorts























Distance from the anal verge
< 5 cm 5 1
5 to 10 cm 7 4
≥ 10 cm 0 1
Chemotherapy
Bevacizumab + FOLFOX (leucovorin, fluorouracil, and oxaliplatin) 11 6
Bevacizumab +5-fluorouracil 1 0
Surgical type
Lower anterior resection 9 3
Abdominoperineal resection 3 1
Wang et al. World Journal of Surgical Oncology 2014, 12:329 Page 4 of 9
http://www.wjso.com/content/12/1/329significantly different between the two groups (P =0.12,
0.25, and 0.22, respectively).
Toxicities
The most common acute toxicities during concurrent
chemoradiotherapy (Table 2) were grade 1 or 2 anal pain
and anemia. Grade 3 toxicity was observed in three pa-
tients (two patients with neutropenia and one with diar-
rhea). There was no febrile neutropenia that required
hospitalization. No difference in treatment-related tox-
icity (except bowel toxicity) was evident between the
supine-position box and prone-position volumetric mod-
ulated arc therapy groups. Five of the six (83%) patients
in the historical cohort and two of the twelve (17%) pa-
tients in the prone volumetric modulated arc therapy
group experienced grade ≥2 diarrhea (P =0.01). Boweltoxicity was probably reduced by the significantly
smaller bowel volume irradiated. The between-group dif-
ferences in average small bowel volumes receiving
35 Gy, 40 Gy, and 45 Gy were all significant (P =0.005,
0.002, and 0.0006, respectively). The dose distribution
(one representative patient from each group) and the
average dose-small bowel volume histogram for each
group are shown in Figure 1.
Surgical outcome
All 12 patients receiving prone volumetric modulated arc
therapy treatment completed neoadjuvant concurrent che-
moradiotherapy with bevacizumab and received total
mesorectal excision. Two patients in the supine box cohort
refused surgery. Pathological responses, including a patho-
logical complete response rate of 33.3%, are shown in
Table 2 Acute toxicities during concurrent chemoradiotherapy
Prone volumetric modulated arc therapy group Supine box group
Grade 1 Grade 2 Grade 3 Grade 1 Grade 2 Grade 3
Anal pain 6 3 0 0 3 0
Diarrhea 0 2 0 0 4 1
Anemia 3 3 0 5 1 0
Neutropenia 3 0 2 2 0 0
Thrombocytopenia 2 0 0 3 0 0
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abscess formation and one postoperative wound infection,
and both resolved after treatment. There was no between-
cohort difference in pathological response (1/4 in the
supine box group versus 4/12 in the prone volumetric
modulated arc therapy group, P =1.00). The hospital stay
was 7 to 24 days (median, 11).
Survival
Kaplan-Meier estimates of failure-free survival and over-
all survival rates are shown in Figure 2. The median esti-
mated survival rate was not reached in both cohorts.
The estimated 2-year survival and 2-year failure-free sur-
vival rates were 100% and 72.9% in the prone volumetric
modulated arc therapy group and 66.7% and 66.7% in
the supine box group, respectively. In the supine box co-
hort, two patients with stage IVA disease were dead at
18.3 and 23.3 months. In the prone volumetric modu-
lated arc therapy group, two patients had locoregional
recurrence and three patients, including those two with
locoregional recurrence, had distant metastasis. All the
failures occurred within 2 years.
Immunohistochemical staining
Owing to the few pathological samples for immunohis-
tochemical study, we combined the two cohorts for ana-
lysis. Postoperative pathology specimens were available
in thirteen patients, while nine of them also had pre-
concurrent chemoradiotherapy specimens. Expression of
CD34 was upregulated in the tumor area after concur-
rent chemoradiotherapy in six of seven patients with less
than pathological complete response and zero of two pa-
tients with pathological complete response (P = 0.08).
Akt was overexpressed in six of nine patients with both
pre-concurrent chemoradiotherapy and postoperative spec-
imens. The expression of vascular endothelial growth factor
receptor 2 and epidermal growth factor receptor did not
differ significantly between pre-concurrent chemoradio-
therapy and postoperative specimens.
Discussion
In this prospective study combined with historical com-
parison, we proposed the technical advantage of using
volumetric modulated arc therapy in patients prone-positioned on a belly board, and reported the early
pathological and clinical results for combined treatment
with bevacizumab and neoadjuvant concurrent chemora-
diotherapy in locally advanced rectal cancer. We demon-
strated that the prone volumetric modulated arc therapy
technique resulted in less toxicity and possibly better
pathological response and clinical outcome. To our
knowledge, this is the first report on survival outcome
and local or distant disease control by neoadjuvant volu-
metric modulated arc therapy in rectal cancer. This
technique allows the concomitant use of oxaliplatin and
bevacizumab, which were previously shown to improve
pathological response in randomized trials. Although ac-
ceptable, the magnitude of setup errors required the use
of image-guided procedures for treatment.
A previous study using preoperative bevacizumab with
FOLFOX and supine box radiotherapy found postopera-
tive complications including delayed healing, leak or ab-
scess, ischemic colonic reservoir, and fistula in 36% of
patients [10]. Our patients had a much lower complica-
tion rate (only 2 of 12 patients) and a more reasonable
postoperative hospital stay (7 to 24 days). An Austrian
group terminated the patient accrual of a phase II trial
combining bevacizumab and capecitabine with three-
field radiotherapy because two of eight patients (25%)
experienced grade 3 diarrhea and intestinal bleeding
[11]. In our study, bowel toxicity was much reduced; the
mean small bowel volume receiving more than 45 Gy
was as small as 24.8 ml. Moreover, the toxicity profile of
our prone volumetric modulated arc therapy approach
was much lower than that in previous studies and that
of our supine box approach. This improvement is bene-
ficial for patients with locally advanced rectal cancer, as
well as selected stage IV patients [20]. Of note, neoadju-
vant chemotherapy without routine use of radiotherapy
was found in a pilot study, and was well tolerable with
no radiation-related side effects [21].
Compared with box techniques, step-and-shoot intensity-
modulated radiation therapy provides superior planning
target volume coverage, dose homogeneity, and conformity;
it decreases the volume of small bowel exposed to radi-
ation, but requires a longer delivery time [12]. Staying in
the prone position on a belly board for such a long treat-
ment period might increase the magnitude of setup errors.
Figure 1 Dose distributions. Axial (left), sagittal (middle), and coronal (right) views of two representative patients treated by (A) supine-position four-field
box radiotherapy and (B) prone-position volumetric modulated arc therapy. Small bowels are contoured in green and gross tumor volume is colored red.
(C) Average dose-volume histogram of small bowels from patients by supine-box technique (dashed line) and prone volumetric modulated arc therapy
technique (solid line).
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ery in a shorter timeframe. In our study, the average deliv-
ery time was as short as 285 s, suggesting a lower
intrafraction motion error.
It was shown that a collapsed cone convolution algo-
rithm might underestimate the dose in water medium
after the photon beam traversed an air gap [19]. Special
attention was suggested for possible setup errors and in-
ternal organ motion. We did not override the density of
rectal gas (if present) during the planning phase. Ac-
cording to our imaging guidance protocol in this study,we used cone-beam computed tomography frequently to
monitor for setup error and internal organ motion. We
did not observe much change in rectal lumen during the
radiotherapy course.
Volumetric modulated arc therapy provided superior
target coverage compared with three-dimensional con-
formal radiotherapy and even step-and-shoot intensity-
modulated radiation therapy in two studies on rectal
cancer and anal cancer [14,15]. Both studies used the su-
pine position. Our volumetric modulated arc therapy ap-
proach used the prone position, which further reduced
Table 3 Pathological stage and response
Outcome Prone volumetric modulatedarc therapy group (n = 12)
Supine box













Figure 2 Kaplan-Meier estimates of failure-free survival and
overall survival of patients with locally advanced rectal cancer
undergoing neoadjuvant bevacizumab and chemoradiotherapy.
The solid line, dashed line, and dotted line represent all 18 patients, 6
patients in the supine box group, and 12 patients in the prone
volumetric modulated arc therapy group, respectively.
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dosimetric study from Italy showed that the same volu-
metric modulated arc therapy approach (compared with
three- or four-field radiotherapy) reduces small bowel
exposure to radiation, and (compared with intensity-
modulated radiation therapy) shortens treatment time
[22]. However, unlike our study, this study did not inves-
tigate clinical outcome (toxicities, magnitude of setup er-
rors, pathological responses, or survivals).
Compared with the traditional four-field box technique,
intensity-modulated radiation therapy or volumetric modu-
lated arc therapy irradiates a smaller pelvic area, mainly the
lymphatic region and the peritumoral area. The issue of
radiotherapy precision by intensity-modulated radiation
therapy or volumetric modulated arc therapy has not been
well addressed in rectal cancer. Pelvic lymphatics are
technically challenging sites to irradiate using intensity-
modulated radiation therapy or volumetric modulated arc
therapy. Our use of image guidance and the corresponding
data on setup errors support our claim of accurate volu-
metric modulated arc therapy delivery. Our results showed
only three patients with pathologically involved lymph
nodes after concurrent chemoradiotherapy, and seven of
ten patients with initial clinical node-positive disease had
an N-downstaging response after volumetric modulated arc
therapy.
Our study revealed increased expression of CD34 (pos-
sibly associated with increased microvessel density) after
concurrent chemoradiotherapy, and increased expression
of Akt before and after concurrent chemoradiotherapy. The
increased expression of Akt after radiotherapy is compatible
with previous reports [23-25]. The data on CD34 expres-
sion after treatment with bevacizumab have been inconsist-
ent [26,27]. Our study revealed a trend toward lower
pathological complete response rate in patients with CD34
upregulation after concurrent chemoradiotherapy. Theincrease in CD34 expression after concurrent chemoradio-
therapy might represent a response of the tumor to treat-
ment. Given the small number of patients in our study, the
true correlation of these markers with the therapeutic re-
sponse will require further investigation.
The limitations of this study include small patient
number, limited follow-up interval, and retrospective
comparison with a previously used supine box technique.
Pre-concurrent chemoradiotherapy and post-concurrent
chemoradiotherapy tumor tissues were only available from
nine patients for evaluation of the therapeutic response
using potential biomarkers. All these limitations might bias
the comparison and endpoints. Although it had a small
number of cases, our study implied that prone-position
volumetric modulated arc therapy has less bowel toxicity
and effectively controls primary tumor and nodal disease.
Consequently, a prospective trial of this method (the sec-
ond cohort) has been initiated in our institution. Serial
magnetic resonance imaging, which was associated with
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in the trial. Further patient enrollment and follow-up are
needed to confirm our early clinical success.
Conclusions
Using volumetric modulated arc therapy in the prone pos-
ition combined with bevacizumab or other novel targeted
agents for locally advanced rectal cancer treatment is feas-
ible and safe, achieves a satisfactory pathological response
and preliminary disease control, and helps reduce bowel
toxicity.
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